Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JUNE 10, 2020

The panel kicked off with a discussion about what types of assets pharmaceutical buyers tend to gravitate toward – both from a general market perspective and from the more specific view of Horizon. The panel also addressed the stage at which a product should be marketed. Key areas of interest for buyers and investors.

M&A 40

M&A Medical Acquisitions Business 40

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

FEBRUARY 15, 2017

We also expect mature, VC-backed companies to continue searching for exit opportunities and may see more “quasi” distressed sales in the first half of the year as their impatience for an IPO market more open to smaller issuers reaches a fever pitch. Negotiating Anti-Reliance Language. Innovation Pressures Fuel M&A.

M&A 40

M&A IPO Pharmaceutical Valuation 40